CHF7.47
3.89% yesterday
SIX Swiss Exchange, Aug 08, 05:31 pm CET
ISIN
IT0004147952
Symbol
NWRN

Newron Pharmaceutical Stock price

CHF7.47
+0.57 8.26% 1M
-2.27 23.31% 6M
-1.48 16.54% YTD
+0.15 2.05% 1Y
+6.05 426.06% 3Y
+5.37 255.71% 5Y
-21.38 74.11% 10Y
-45.63 85.93% 20Y
SIX Swiss Exchange, Closing price Fri, Aug 08 2025
+0.28 3.89%
ISIN
IT0004147952
Symbol
NWRN
Industry

Key metrics

Basic
Market capitalization
CHF143.5m
Enterprise Value
CHF181.8m
Net debt
CHF38.3m
Cash
CHF9.3m
Shares outstanding
20.0m
Valuation (TTM | estimate)
P/E
9.3 | negative
P/S
3.0 | 12.8
EV/Sales
3.8 | 16.2
EV/FCF
negative
P/B
104.8
Financial Health
Equity Ratio
2.3%
Return on Equity
1,086.6%
ROCE
64.8%
ROIC
39.5%
Debt/Equity
34.7
Financials (TTM | estimate)
Revenue
CHF48.4m | CHF11.2m
EBITDA
CHF24.8m | CHF-26.5m
EBIT
CHF24.6m | CHF-26.8m
Net Income
CHF14.9m | CHF-31.4m
Free Cash Flow
CHF-16.6m
Growth (TTM | estimate)
Revenue
467.2% | -76.9%
EBITDA
330.7% | -206.8%
EBIT
325.1% | -208.6%
Net Income
197.7% | -310.3%
Free Cash Flow
-73.6%
Margin (TTM | estimate)
Gross
98.3%
EBITDA
51.3% | -236.7%
EBIT
50.9%
Net
30.8% | -280.2%
Free Cash Flow
-34.3%
More
EPS
CHF0.8
FCF per Share
CHF-0.8
Short interest
-
Employees
22
Rev per Employee
CHF2.2m
Show more

Is Newron Pharmaceutical a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Newron Pharmaceutical Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Newron Pharmaceutical forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Newron Pharmaceutical forecast:

Buy
88%
Hold
13%

Financial data from Newron Pharmaceutical

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
48 48
467% 467%
100%
- Direct Costs 0.84 0.84
91% 91%
2%
48 48
488% 488%
98%
- Selling and Administrative Expenses 11 11
55% 55%
22%
- Research and Development Expense 12 12
1% 1%
25%
25 25
331% 331%
51%
- Depreciation and Amortization 0.18 0.18
5% 5%
0%
EBIT (Operating Income) EBIT 25 25
325% 325%
51%
Net Profit 15 15
198% 198%
31%

In millions CHF.

Don't miss a Thing! We will send you all news about Newron Pharmaceutical directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Newron Pharmaceuticals SpA operates as a biopharmaceutical company. It focuses on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The firm's products include Xadago (safinamide), Evenamide (NW-3509) and Ralfinamide. The company was founded by Luca Benatti, Ruggero Fariello and Patricia Salvati in 1999 and is headquartered in Bresso, Italy.

Head office Italy
CEO Stefan Weber
Employees 22
Founded 2002
Website www.newron.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today